FIGURE 5

FIGURE 5

Chemosensitive profiling in zPDXs of patient #20 and its clinical relevance. (A) Patient #20 was diagnosed as diffuse-type gastric adenocarcinoma. (B,C) His zPDXs study showed that 5-FU was the only sensitive drug (*P < 0.05). (D) The patient had elevated preoperative serum AFP level (13.30 ng/ml), and his serum AFP level went down to normal range after radical surgery. He initially received postoperative TP (oxaliplatin/paclitaxel) therapy, but his serum AFP increased to 16.4 ng/ml at postoperative 6 months. (E) He received CT scan at postoperative 1 month as baseline and no abnormality was found. (F) However, his MR monitoring showed one metastatic foci (red ring) in the right lobe of his liver at postoperative 6 months. Thus, he was considered to relapse. The regimen was adjusted to capecitabine (Cap, a prodrug of 5-FU). Two cycles later, his serum AFP level returned to the normal range, and stayed for more than 5 months.